CRISPR Therapeutics AG (CRSP): Price and Financial Metrics

CRSP POWR Grades

• CRSP scores best on the Growth dimension, with a Growth rank ahead of 94.63% of US stocks.
• The strongest trend for CRSP is in Momentum, which has been heading down over the past 177 days.
• CRSP ranks lowest in Stability; there it ranks in the 1st percentile.

CRSP Stock Summary

• Of note is the ratio of CRISPR THERAPEUTICS AG's sales and general administrative expense to its total operating expenses; just 4.57% of US stocks have a lower such ratio.
• CRSP's price/sales ratio is 24.84; that's higher than the P/S ratio of 95.47% of US stocks.
• As for revenue growth, note that CRSP's revenue has grown 1,106.49% over the past 12 months; that beats the revenue growth of 99.2% of US companies in our set.
• Stocks that are quantitatively similar to CRSP, based on their financial statements, market capitalization, and price volatility, are RVMD, XBIT, CKPT, RLAY, and NRIX.
• CRSP's SEC filings can be seen here. And to visit CRISPR THERAPEUTICS AG's official web site, go to www.crisprtx.com.

CRSP Valuation Summary

• CRSP's price/earnings ratio is -9.7; this is 139.92% lower than that of the median Healthcare stock.
• CRSP's price/sales ratio has moved down 345.2 over the prior 86 months.

Below are key valuation metrics over time for CRSP.

CRSP Growth Metrics

Its year over year net income to common stockholders growth rate is now at 179.43%.
• Its 5 year net cashflow from operations growth rate is now at 187.22%.
• Its 5 year cash and equivalents growth rate is now at 180.78%.

Over the past 33 months, CRSP's revenue has gone down $275,499,000.

The table below shows CRSP's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	14.091	-468.451	-680.848
2022-06-30	14.821	-444.562	-633.452
2022-03-31	915.364	504.396	311.607
2021-12-31	914.963	538.972	377.661
2021-09-30	902.434	543.798	411.87
2021-06-30	901.758	549.427	446.584

CRSP's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• CRSP has a Quality Grade of C, ranking ahead of 73.06% of graded US stocks.
• CRSP's asset turnover comes in at 0.441 -- ranking 101st of 681 Pharmaceutical Products stocks.
• CDTX, NVS, and SEEL are the stocks whose asset turnover ratios are most correlated with CRSP.

The table below shows CRSP's key quality metrics over time.